Administration of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy; a new strategy in the management?

Yeganeh Ragati Haghi ¹ , Anastasia Dieti ² , Majid Forootan ³^*

¹ Massachusetts College of Pharmacy and Health Sciences - Worcester Campus: Worcester, MA, USA
² Independent Researcher, 6 Onisilou Street, Dasoupolis 2015, Nicosia, Cyprus
³ Department of Internal Medicine, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran

*Corresponding Author: Corresponding author: Majid Forootan, Email: , Email: dr_forotan@yahoo.com

Abstract

Some of the several effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including their metabolic, anti-inflammatory and hemodynamic properties, along with other kidney protective values, have directed clinicians to give these drugs in IgA-nephropathy (IgAN). According to recent studies regarding the beneficial effects of SGLT-2i on IgAN, it is clear that clinicians are changing their approach towards kidney transplantation when it comes to aggressive immunosuppression. This mini-review aims towards the evaluation of the protective efficacy of SGLT-2i in IgA-nephropathy.

Keywords: Sodium-glucose cotransporter-2 inhibitors, Chronic kidney disease, IgA-nephropathy, Diabetic kidney disease, Acute kidney disease, Albuminuria

Implication for health policy/practice/research/medical education:

Sodium-glucose cotransporter-2 inhibitors can provide a new strategy to prevent progression of chronic renal failure in individuals with IgA-nephropathy.

Please cite this paper as: Ragati Haghi Y, Dieti A, Forootan M. Administration of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy; a new strategy in the management? J Nephropathol. 2023;12(2):e21429. DOI: 10.34172/jnp.2023.21429.